NV-VERACODE
1.8.2024 13:56:35 CEST | Business Wire | Press release
Black Hat USA Conference (booth #2536) – Veracode, a global leader in application risk management, today announced platform innovations to help organizations uncover, prioritize, and reduce security debt across their growing attack surface. Universal Connector and Application Security Heatmap, the two newest capabilities from Longbow powered by Veracode, allow organizations to quickly connect findings from any source and see the applications that are contributing to the most risk. Together, the Universal Connector and the Application Security Heatmap provide clear, operational insight into assets and issues, allowing remediation actions to be prioritized by quantifiable risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801020287/en/
Figure 1: State of Software Security 2024 Language Snapshot (Graphic: Business Wire)
“The combination of mounting security debt, an expanding attack surface made more vulnerable by generative AI, and an overwhelming volume of security alerts makes it challenging for organizations to know which application risks to prioritize,” said Chris Eng, Chief Research Officer at Veracode. “In fact, our State of Software Security research shows that many organizations are more focused on remediating low-severity flaws than critical flaws. Security leaders need technology that enables them to effectively uncover and manage application risk, and then reduce that risk by focusing on the issues that matter most across their entire attack surface.”
Prioritization of Security Debt: Critical vs Non-critical
In its State of Software Security 2024 Language Snapshot, Veracode revealed the varying prevalence of “critical” and “non-critical” security debt among applications written in different languages. Critical security debt is defined for this report as high-severity flaws that remain unfixed for longer than a year. If exploited, these flaws would put the integrity and availability of organizations at serious risk.
The research found that while most security debt exists in first-party code written by in-house developers, the most critical security debt resides in third-party code (e.g., open-source software imported into the codebase). For example, 80 percent of critical debt in Java apps, and 63 percent in JavaScript apps, is in third-party code. The report also found about 51 percent of critical flaws in Java apps turn into security debt, while only about 45 percent of low to medium flaws progress into security debt.
Eng said, “With the overflowing volume of security flaws, developers are not prioritizing those that present the most risk. While focusing on non-critical flaws may result in some quick fixes, developers should use their limited capacity to work on fixing critical flaws with the highest potential impact on security.”
Putting Visibility and Prioritization First: Universal Connector & Application Security Heatmap
Building on Veracode’s acquisition of Longbow Security in April this year, and the introduction of Longbow’s Repo Risk Visibility and Analysis capability in May, Universal Connector and Application Security Heatmap are designed with developers’ time in mind. The capabilities provide operational oversight to help developers and security teams quickly identify and prioritize the most important fixes for growing security debt across their applications.
Universal Connector allows organizations to quickly access disparate source data they otherwise couldn’t bring into the Longbow platform, meaning they don’t have to wait for a tool-specific connector. The Application Security Heatmap maps the application back to the owner and shows a 90-day risk trend, as well as enabling customization of the risk threshold to meet organizational policy. Application security teams and developers can analyze each application, view the distribution of risk, and implement recommendations for the Best Next Action™ to remediate that risk.
“As organizations seek to find and fix mounting critical security debt, the need for risk-focused visibility and prioritization is clear,” said Derek Maki, Vice President of Product Management at Veracode. “The new capabilities in the Longbow platform provide our customers with a deeper understanding of an organization’s riskiest applications, plus the unique ability to identify the top five most impactful solutions for improvement.”
Enhanced by the Longbow acquisition, Veracode closes the gap between development and security teams, delivering visibility from code repositories to cloud assets and runtime. Longbow also identifies infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.
The Longbow Universal Connector and Application Security Heatmap are available immediately. For more information, please visit the website or watch the interview with Brian Roche, Veracode Chief Executive Officer, and Derek Maki.
The full State of Software Security 2024 Language Snapshot is available on the Veracode website.
Visitors to the Black Hat USA Conference, August 3-8, 2024, can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2536 for a demo.
About the State of Software Security Report
The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801020287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
